跳至主要内容
临床试验/NCT03566069
NCT03566069进行中(未招募)2 期

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness: A Randomized Controlled Study

Shalvata Mental Health Center1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2018年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
120
试验地点
1
主要终点
Change in Depression and Anxiety Symptoms

研究概览

简要总结

Intranasal administration of Oxytocin (OT) has been found to improve social communication skills and encoding of social cues. Studies indicate that the provision of OT enhances the ability to develop trust 1, to improve the benefits of social support during social stress induction tasks 2 and to increase positive communication during couples' conflict discussions 3. These studies, and many others, point to the potential beneficial effects of OT as a facilitator of relationship-focused processes such as psychotherapy. Studies assessing the effect of OT as a possible outcome enhancer in psychotherapy for clinical populations are scarce, and their findings are largely inconsistent 4. Reasons for this state of affairs include the complexity of recruitment in this population; the provision of single-dose OT, which tends to cause a lower and insufficient effect 5; and methodological constraints, such as the lack of a control group 6 or insufficient probing of interpersonal factors 7.

In this study we intend to overcome these constraints by evaluating the impact of intranasal administration of OT in patients suffering from acute stages of anxiety and depression disorders and undergoing intensive, relationship-focused psychotherapy during psychiatric hospitalization. One-hundred-and-twenty admitted patients with anxiety and depression disorders will be randomized and double-blindly allocated to two groups: (a) psychotherapy + OT (n=60), and (b) psychotherapy + placebo (n=60). Patients will be followed for three weeks, beginning at the start of their hospitalization, and will be assessed for the severity of their anxiety and depression symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day.

This study can provide insights regarding the potential involvement of OT in the trajectories leading to the production of detectable changes in brain activity following psychotherapy. Additionally, it can support the development of an integrating model combining recent findings in psychotherapy research pertaining to the significant role of therapeutic alliance in psychotherapy outcome, and findings from neuroimaging studies. Finally, provision of OT as a psychotherapy enhancer can facilitate a rapid therapeutic response and subsequently replace aggressive psychiatric medication usage, needed to create a rapid decrease of distress during psychiatric admissions.

详细描述

  1. Introduction 1.1 Oxytocin (OT) OT is a nine-amino acid neuropeptide synthesized in the magnocellular neurons of the paraventricular (PVN) and supraoptic nuclei (SON) of the hypothalamus, and released by the pituitary gland (Meyer-Lindenberg, Domes, Kirsch, & Heinrichs, 2011). OT has both peripheral and central effects, and serves as a neurotransmitter, a neuromodulator and a hormone (see reviews in de Bono, 2003; Skuse & Gallagher, 2009). Peripherally, it is released from the posterior pituitary into the bloodstream where it functions as a hormone and influences bodily functions, such as regulating uterine contractions during labor and lactation (Keverne & Kendrick, 1992). Centrally, through direct axonal release from the PVN, OT acts as a neurotransmitter projecting to various critical brain structures rich with OT receptors such as the hippocampus, amygdala, striatum, and nucleus accumbens (Landgraf & Neumann, 2004;Macdonald & Macdonald, 2010; Ross & Young, 2009). As a neuromodulator, OT creates general volume diffusion, as it is released from all parts of the neuronal membrane into the extracellular space, affecting many regions of the brain (Landgraf & Neumann, 2004; Leng, Meddle, & Douglas, 2008; Ludwig & Leng, 2006).

1.2. Oxytocin and Social Behavior Perhaps one of the most well-known associations of OT is with social behavior. Often referred to as the "social bonding" hormone, OT has been consistently found to be involved in the formation and management of social bonds and in the promotion of affiliative prosocial behavior (Theodoridou, Rowe, Penton-Voak, & Rogers, 2009). Several studies have shown that OT administration increases cooperation, generosity and trust in others. For example, Mikolajczak et al. (2010) investigated the role of OT in interpersonal trust, by evaluating participants' willingness to take social risks compared to nonsocial risks. They found that participants who received IN-OT showed higher levels of trust, and expressed willingness to take risks during social (but not general) interactions, as compared to the placebo group. Similarly, Zak et al. (2007) infused participants with IN-OT or placebo before engaging in a blinded money gifting generosity game, in which there had to make a one-shot decision on how to split a sum of money with a stranger. Their findings indicated that participants in the IN-OT group were 80% more generous than those given a placebo (Zak et al., 2007). In an attempt to assess the neural correlatives of the OT-trust association, Baumgartner, Heinrichs, Vonlanthen, Fischbacher, & Fehr, (2008) assessed participants willingness to trust others even in light of a possible betrayal. They found that participants who had received IN-OT continued to show trusting behavior, even though their trust had been betrayed, as opposed to participants in the placebo group. During this task, they found reduced neural activation in the amygdala and caudate nucleus among participants receiving IN-OT, brain areas which are known to be involved in fear processing (amygdala) and behavioral adaptation (caudate nucleus) in situations with unknown outcome contingencies (Baumgartner, Heinrichs, Vonlanthen, Fischbacher, & Fehr, 2008).

Several studies have put forth the hypothesis that OT is responsible primarily to pro-social behavior. For example, Guastella, et al., (2008) presented participants with happy, angry, or neutral human faces after receiving IN-OT\placebo, and then tested their memory of these faces. They found that participants administered with OT were more likely to remember previously seen happy faces compared with angry and neutral human faces. These findings have indicated that OT has specific influence aimed encoding and recalling positive social information (Guastella, et al., 2008). In another double-blind, placebo-controlled study, Domes et al., (2007) evaluated male volunteers' ability to infer the affective mental state of others using the Reading the Mind in the Eyes Test (RMET) after IN-OT\placebo. They found that IN-OT significantly improved performance on the RMET compared with placebo, suggesting that OT facilitate the interpretation of subtle social cues from eye regions (Domes, Heinrichs, Michel, Berger, & Herpertz, 2007). These, as well the previous studies on the effect of OT on trust and generosity, have set grounds for the hypothesis suggesting OT is responsible for pro-social behavior.

Although many studies have demonstrated an association between OT and pro-social behavior, other studies have found some contradicting findings which called the pro-social hypothesis into question. These studies have seemed to demonstrate that OT, under specific contexts, might actually induce a negative effect on social behavior. For example, Shamay-Tsoory et al., (2009) found that OT administration increased feelings of envy in a simulated money game when the other player gained more money, and feelings of gloating during the experience of success. Eckstein et al., (2014) exposed participants to social stress following IN-OT\placebo administration, and found that participants in the OT group reported increased perceived social stress, as well as increased activity in the precuneus and cingulate cortex, areas which are known to be sensitive to signals of social stress. Striepens et al., (2012) found that IN-OT enhanced the impact of negative social stimuli on the induction of startle response, and induced the subsequent memory toward negative rather than neutral items. Using fMRI analysis, the authors also demonstrated that despite reducing amygdala activity, IN-OT have increased the impact of aversive social information by increasing neural responses in the insular cortex - which play a role in emotional modulation of memory.

A proposed theoretical framework that has been suggested to reconcile these seemingly conflicting studies is "The social salience hypothesis" (Shamay-Tsoory & Abu-Akel, 2016). According to this hypothesis, OT may increase the salience of safety signals, attenuate stress and promote social approach in positive supportive contexts, yet increase the salience of threat signals, diminish social approach and increase anxiety in unpredictable threatening situations. In other words, this hypothesis suggests that OT affects human behavior in an adaptive and context-dependent manner (Andari, Hurlemann, & Young, 2017). It has been suggested that the underlying mechanism which associates OT with modulation of salience throughout different contexts is through the role of OT in attentional processes. OT receptors are found in visual associative areas in humans (Freeman and Young 2016) and in regions involved in attention such as the diagonal band of Broca (Freeman et al. 2014). Moreover, IN-OT has been found to increases visual fixation towards communicative areas of the face such as the eye regions (Guastella et al. 2008), and has also been found to improve the capacity to read subtle non-verbal cues from eye regions, through which individuals understand the intentions and behaviors of social partners (Domes, Heinrichs, Michel, Berger, & Herpertz, 2007). These findings have put forth the idea that OT operates through the induction of attentional shifts towards important social information, and thereby increase the salience of socially relevant cues.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis: Transdiagnostic (e.g. depression, anxiety disorders, OCD, personality disorders, PTSD, etc.).
  • Expected length of hospitalization of at least 4 weeks
  • A physical and psychiatric evaluation will be conducted in admission to hospital

排除标准

  • Pregnancy (bHCG levels will be tested in fertile-aged female patients)
  • Patients undergoing ECT
  • Substance abuse comorbidity (not including cigarette smoking)
  • Psychotic, AS or mental retardation spectrum disorders
  • Potential suicidal risk (SSI>12) - requiring approval of treating psychiatrist

研究组 & 干预措施

Experimental Group

Experimental

After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.

干预措施: Intranasal Oxytocin (Drug)

Placebo Group

Placebo Comparator

After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.

干预措施: Intranasal Placebo (Other)

结局指标

主要结局

Change in Depression and Anxiety Symptoms

时间窗: assessing change over 10 time points, at baseline, twice a week after psychotherapy sessions over a month of intervention and at Follow-Up a month post intervention for each participant

As measured repeatedly by the Hopkins symptoms checklist -short form (HSCL-11) (Lutz, Tholen, Schurch, \& Berking, 2006)

次要结局

  • Change in Therapeutic Working Alliance(assessing change over 8 time points (twice a week after psychotherapy sessions) during the month of the intervention for each participant)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验